Galectin Therapeutics (GALT) Earnings Date, Estimates & Call Transcripts → FW: 234x Gain (From Weiss Ratings) (Ad) Free GALT Stock Alerts $3.34 -0.03 (-0.89%) (As of 05/3/2024 ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Earnings SummaryUpcoming Earnings DateMay. 20EstimatedActual EPS (Mar. 29) -$0.16 Missed By -$0.16 Get Galectin Therapeutics Earnings AlertsEnter your email address below to receive the latest news and earnings results for GALT and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueGALT Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.GALT Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad InvestorPlaceWatch this FREE trading tutorial while it’s still availableOn Wednesday, May 8, the legendary Jonathan Rose is holding his first ever Masters in Trading Summit. Jonathan is one of the sharpest traders I’ve ever met. He made millions trading in the pits of the world’s largest exchanges.Click here for details. Galectin Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20241($0.16)($0.16)($0.16)Q2 20241($0.16)($0.16)($0.16)Q3 20241($0.17)($0.17)($0.17)Q4 20241($0.17)($0.17)($0.17)FY 20244($0.66)($0.66)($0.66)GALT Earnings Date and InformationGalectin Therapeutics last released its quarterly earnings results on March 29th, 2024. The reported ($0.16) earnings per share (EPS) for the quarter. Galectin Therapeutics has generated ($0.74) earnings per share over the last year (($0.74) diluted earnings per share). Earnings for Galectin Therapeutics are expected to decrease in the coming year, from ($0.66) to ($1.59) per share. Galectin Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 20th, 2024 based off prior year's report dates.Read More Galectin Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 5/20/2024Estimated)------- 3/29/2024Q4 2023-($0.16)($0.16)($0.16)--11/13/2023Q3 2023($0.16)($0.24)($0.08)($0.24)--8/14/2023Q2 2023($0.21)($0.15)+$0.06($0.15)--5/15/2023Q1 2023($0.21)($0.19)+$0.02($0.19)--3/30/2023Q4 2022($0.17)($0.18)($0.01)($0.18)--11/14/2022Q3 2022($0.20)($0.14)+$0.06($0.14)-- Get the Latest News and Ratings for GALT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Galectin Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/15/2022Q2 2022($0.19)($0.16)+$0.03($0.16)--5/16/2022Q1 2022($0.10)($0.17)($0.07)($0.17)--3/31/2022Q4 2021-($0.13)($0.13)($0.14)--11/15/2021Q3 2021($0.18)($0.14)+$0.04($0.14)--8/16/2021Q2 2021($0.18)($0.15)+$0.03($0.15)--5/16/2021Q1 2021($0.17)($0.11)+$0.06($0.11)-- Galectin Therapeutics Earnings - Frequently Asked Questions When is Galectin Therapeutics's earnings date? Galectin Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 20th, 2024 based off last year's report dates. Learn more on GALT's earnings history. How much profit does Galectin Therapeutics generate each year? Galectin Therapeutics (NASDAQ:GALT) has a recorded net income of -$41.07 million. GALT has generated -$0.74 earnings per share over the last four quarters. What is Galectin Therapeutics's EPS forecast for next year? Galectin Therapeutics's earnings are expected to decrease from ($0.66) per share to ($1.59) per share in the next year. More Earnings Resources from MarketBeat Related Companies: DSGN Earnings PRLD Earnings MACK Earnings GBIO Earnings OGI Earnings RIGL Earnings GTHX Earnings ZVRA Earnings FHTX Earnings TRVI Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Apple’s Earnings Show Investors Its Strength and Its WeaknessCarvana’s Q1 Earnings: A Profitability U-TurnPayPal’s Strong Earnings Growth and Strategic Evolution GE Aerospace is Ready for Liftoff After Strong EarningsTaiwan Semiconductor Earnings: AI Dominance and Future OutlookCSX Co.: The Railroad Powering Ahead with an Earnings Beat What's Driving Tesla Lower Ahead of its Earnings? This page (NASDAQ:GALT) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersCould Your Accounts Be Frozen?Allegiance GoldAutomatic Income (from home)Awesomely, LLCGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchForget Nvidia. This is the future of AIPorter & CompanyHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceThe asset beating inflation by 4xColonial MetalsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galectin Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.